Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

In a 12-week MASLD trial, pemvidutide (a GLP-1/glucagon dual agonist) markedly reduced liver fat and improved cT1 versus placebo, alongside improvements in body weight and liver enzymes. A high proportion achieved clinically meaningful cT1 reductions. Treatment was well tolerated without serious adverse events, supporting pemvidutide as a promising therapy.